Fulgent Genetics (FLGT) Cash from Financing Activities (2016 - 2026)

Fulgent Genetics has disclosed Cash from Financing Activities across 11 years of filings, most recently posting -$44.8 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$44.8 million, down 301.3% year-over-year; the trailing twelve-month figure through Mar 2026 was -$48.4 million (down 266.71% YoY), and the FY2025 annual result was -$14.8 million, down 205.12% from the prior year.
• Cash from Financing Activities came in at -$44.8 million for Q1 2026 at Fulgent Genetics, down from -$534000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of -$327000.0 in Q4 2024 to a low of -$44.8 million in Q1 2026.
• The 5-year median for Cash from Financing Activities is -$2.8 million (2024), against an average of -$11.1 million.
• Across the five-year window, Cash from Financing Activities plunged 1086.42% in 2022 and surged 98.74% in 2024, its largest moves.
• Fulgent Genetics' Cash from Financing Activities stood at -$29.6 million in 2022, then grew by 12.31% to -$26.0 million in 2023, then soared by 98.74% to -$327000.0 in 2024, then slumped by 63.3% to -$534000.0 in 2025, then tumbled by 8295.69% to -$44.8 million in 2026.
• The last three Cash from Financing Activities figures came in at -$44.8 million (Q1 2026), -$534000.0 (Q4 2025), and -$445000.0 (Q3 2025), per Business Quant data.